 Anandani Nellan
Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 5 | 2022 | 987 | 0.810 |
Why?
| | Proto-Oncogene Proteins B-raf | 2 | 2020 | 193 | 0.790 |
Why?
| | Pituitary Diseases | 1 | 2020 | 23 | 0.730 |
Why?
| | Cerebellar Neoplasms | 2 | 2022 | 131 | 0.720 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2020 | 35 | 0.720 |
Why?
| | Retinal Neoplasms | 1 | 2020 | 21 | 0.710 |
Why?
| | Retinoblastoma | 1 | 2020 | 26 | 0.710 |
Why?
| | Medulloblastoma | 2 | 2022 | 172 | 0.710 |
Why?
| | Pituitary Gland | 1 | 2020 | 148 | 0.690 |
Why?
| | Glioma | 2 | 2020 | 296 | 0.690 |
Why?
| | Immunotherapy, Adoptive | 2 | 2019 | 184 | 0.670 |
Why?
| | Receptor, ErbB-2 | 1 | 2018 | 301 | 0.520 |
Why?
| | Antigens, CD19 | 1 | 2015 | 91 | 0.500 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2015 | 64 | 0.480 |
Why?
| | Ependymoma | 3 | 2022 | 157 | 0.450 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 666 | 0.450 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2019 | 620 | 0.420 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 1361 | 0.410 |
Why?
| | Immunotherapy | 1 | 2015 | 475 | 0.390 |
Why?
| | Central Nervous System Neoplasms | 2 | 2022 | 126 | 0.330 |
Why?
| | Macaca mulatta | 2 | 2018 | 131 | 0.300 |
Why?
| | T-Lymphocytes | 4 | 2020 | 1749 | 0.300 |
Why?
| | Administration, Intravenous | 2 | 2018 | 125 | 0.300 |
Why?
| | Biomarkers, Tumor | 2 | 2019 | 1054 | 0.210 |
Why?
| | Vinblastine | 1 | 2020 | 62 | 0.180 |
Why?
| | Carboplatin | 1 | 2020 | 135 | 0.170 |
Why?
| | Child, Preschool | 4 | 2020 | 9086 | 0.170 |
Why?
| | Mutation | 3 | 2020 | 3353 | 0.170 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 17 | 0.170 |
Why?
| | Neoplasm Grading | 1 | 2020 | 243 | 0.170 |
Why?
| | B7 Antigens | 1 | 2019 | 9 | 0.160 |
Why?
| | Infusions, Intraventricular | 1 | 2018 | 4 | 0.160 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 71 | 0.150 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 104 | 0.150 |
Why?
| | Administration, Intranasal | 1 | 2018 | 75 | 0.150 |
Why?
| | Half-Life | 1 | 2018 | 141 | 0.150 |
Why?
| | Supratentorial Neoplasms | 1 | 2018 | 17 | 0.150 |
Why?
| | Polymerase Chain Reaction | 1 | 2020 | 995 | 0.150 |
Why?
| | Oncogene Proteins, Fusion | 1 | 2019 | 179 | 0.150 |
Why?
| | Area Under Curve | 1 | 2018 | 275 | 0.150 |
Why?
| | Cell Line, Tumor | 3 | 2019 | 2725 | 0.150 |
Why?
| | Blood-Brain Barrier | 1 | 2018 | 106 | 0.150 |
Why?
| | Transcription Factor RelA | 1 | 2018 | 83 | 0.150 |
Why?
| | Antigens, Neoplasm | 1 | 2019 | 222 | 0.140 |
Why?
| | Autophagy | 1 | 2019 | 234 | 0.140 |
Why?
| | Follow-Up Studies | 3 | 2020 | 4427 | 0.140 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 142 | 0.130 |
Why?
| | Male | 7 | 2020 | 55663 | 0.130 |
Why?
| | Survival Rate | 1 | 2020 | 1644 | 0.130 |
Why?
| | Dyskeratosis Congenita | 1 | 2015 | 4 | 0.130 |
Why?
| | Animals | 5 | 2022 | 31837 | 0.130 |
Why?
| | Child | 5 | 2022 | 18366 | 0.130 |
Why?
| | Exoribonucleases | 1 | 2015 | 40 | 0.130 |
Why?
| | Microcephaly | 1 | 2015 | 52 | 0.120 |
Why?
| | Intellectual Disability | 1 | 2015 | 130 | 0.120 |
Why?
| | Mice, Transgenic | 1 | 2018 | 1953 | 0.110 |
Why?
| | Cytokines | 1 | 2020 | 1843 | 0.110 |
Why?
| | Infant | 3 | 2020 | 7937 | 0.100 |
Why?
| | Humans | 11 | 2022 | 114935 | 0.100 |
Why?
| | Female | 5 | 2020 | 59580 | 0.100 |
Why?
| | Fetal Growth Retardation | 1 | 2015 | 467 | 0.090 |
Why?
| | Mice | 3 | 2022 | 14935 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2022 | 12544 | 0.090 |
Why?
| | Infant, Newborn | 1 | 2020 | 5035 | 0.080 |
Why?
| | Tumor Microenvironment | 2 | 2022 | 434 | 0.080 |
Why?
| | Adolescent | 2 | 2020 | 17829 | 0.060 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 90 | 0.050 |
Why?
| | Prognosis | 2 | 2019 | 3344 | 0.050 |
Why?
| | Leukocytes | 1 | 2022 | 277 | 0.050 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 173 | 0.050 |
Why?
| | Aminopyridines | 1 | 2019 | 81 | 0.040 |
Why?
| | Benzamides | 1 | 2019 | 169 | 0.040 |
Why?
| | Blotting, Western | 1 | 2019 | 1151 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1126 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2022 | 1148 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 378 | 0.030 |
Why?
| | Transcriptome | 1 | 2022 | 728 | 0.030 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2019 | 706 | 0.030 |
Why?
| | Cell Survival | 1 | 2019 | 1022 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1087 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2018 | 347 | 0.030 |
Why?
| | Exome | 1 | 2015 | 201 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2015 | 372 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2019 | 1635 | 0.030 |
Why?
| | Young Adult | 2 | 2018 | 10478 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1523 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6218 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2019 | 3549 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2382 | 0.020 |
Why?
| | Cohort Studies | 1 | 2018 | 4903 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9105 | 0.020 |
Why?
| | Adult | 1 | 2018 | 30608 | 0.010 |
Why?
|
|
Nellan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|